Reply to Merli et al.
Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Patrick R
PR
Harrington
Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Russell
R
Fleischer
Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Sarah M
SM
Connelly
Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Linda L
LL
Lewis
Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Jeffrey
J
Murray
D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D008231:Lymphopenia / Q000139:chemically induced*; D012254:Ribavirin / Q000008:administration & dosage* / Q000009:adverse effects*
D000998:Antiviral Agents; D012254:Ribavirin